200 mg/m 2 melphalan-the gold standard for multiple myeloma

Nature Reviews Clinical Oncology

Volumn 7, Issue 9, 2010, Pages 490-491

  Giralt, Sergio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; INFECTION; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; SHORT SURVEY; WHOLE BODY RADIATION;

AGE FACTORS; ANTINEOPLASTIC AGENTS, ALKYLATING; DISEASE PROGRESSION; GREAT BRITAIN; HUMANS; MELPHALAN; MULTIPLE MYELOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77956260736     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.104     Document Type: Short Survey

References (10)

1. 2 in newly diagnosed myeloma patients: a prospective multicenter phase 3 study. Blood 115, 1873-1879 (2010).
2. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the intergroupe Francophone du Myélome 9502 randomized trial. Blood 99, 731-735 (2002).
3. Cavo, M. et al. superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide- dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood 112, a158 (2008).
4. Harousseau, J. L. et al. velcade/dexamethasone (vel/D) versus vAD as induction treatment prior to autologous stem cell transplantation (AsCT) in newly diagnosed multiple myeloma (MM): updated results of the iFM 2005/01 trial [abstract]. Blood 110, a450 (2007).
5. Chanan-Khan, A. A. & Giralt, S. importance of achieving a complete response in multiple myeloma and the impact of novel agents. J. Clin. Oncol. 28, 2612-2624 (2010).
6. Wang, X. S. et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 1319-1328 (2002).
7. Anderson, K. O. et al. symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant. 39, 759-766 (2007).
8. Phillips, G. L. et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase i study. Biol. Blood Marrow Transplant. 10, 473-483 (2004).
9. Moreau, P. et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized iFM 99-04 protocol. Blood 107, 397-403 (2006).
10. Badros, A. Z. The role of maintenance therapy in the treatment of multiple myeloma. J. Natl Compr. Canc. Netw. 8 (suppl. 1), s21-s27 (2010).